Quantcast

Latest Eisai Co. Ltd. Stories

2011-08-29 12:20:01

Tokyo, Aug 29, 2011 - (JCN Newswire) - Abbott Japan Co., Ltd. and Eisai Co., Ltd. announced today that they will launch the pancreatic digestive enzyme replacement drug Lipacreon(R) Capsules 150 mg and Lipacreon(R) Granules 300mg Sachets (pancrelipase) on August 30 in Japan.Abbott Japan received approval to manufacture and market Lipacreon in Japan as a pancreatic digestive enzyme replacement in patients with pancreatic exocrine insufficiency (PEI) on April 22 of this year, with the drug...

2011-08-10 04:35:01

Tokyo, Aug 10, 2011 - (JCN Newswire) - Eisai Co., Ltd. and its diagnostics subsidiary EIDIA Co., Ltd announced today that EIDIA received approval on August 8, 2011 to manufacture and market PROTOCO2L, Japan's first carbon dioxide insufflation system for use as a medical device in CT Colonography, along with the carbon dioxide insufflation tube PROTOCO2L Catheter Set (collectively referred to as "the Product").Carbon dioxide insufflation systems are widely utilized in the United States and...

2011-07-19 12:35:02

Tokyo, July 19, 2011 - (JCN Newswire) - Eisai Co., Ltd. today announced the launch of its novel anticancer agent Halaven(R) in Japan for the treatment of inoperable or recurrent breast cancer. Halaven(R) is the first novel anticancer agent to be discovered and developed by the Eisai. Having simultaneously submitted marketing authorization applications to the regulatory authorities in Japan, the United States and the European Union (EU) in March 2010, the company first launched Halaven(R) in...

2011-07-01 08:35:02

Tokyo, July 1, 2011 - (JCN Newswire) - Abbott Japan Co., Ltd. and Eisai Co., Ltd. announced today that they have received approval from Japan's Ministry of Health, Labour, and Welfare (MHLW) for polyarticular juvenile idiopathic arthritis (JIA) as an additional indication of Humira(R) (adalimumab) Pre-filled Syringe 40 mg/0.8 mL for Subcutaneous Injection, a fully human anti-TNF-α monoclonal antibody jointly developed by the two companies in Japan.In addition to the new indication,...

2011-04-22 04:35:01

Tokyo, Apr 22, 2011 - (JCN Newswire) - Eisai Co., Ltd. (TSE: 4523) announced today that it has received approval to market its novel anticancer Halaven(R) Injection 1mg (eribulin mesylate) in Japan for the treatment of inoperable and recurrent breast cancer. Discovered and developed by Eisai, Halaven is now approved in each of the world's three largest pharmaceutical markets, comprising Japan, the United States and the European Union (EU).The Japan marketing authorization application for...

2010-09-30 08:35:01

Tokyo, Sept 29, 2010 - (JCN Newswire) - Eisai Co., Ltd. and Shinshu University venture company Anaeropharma Science, Inc. today announced that they have concluded an option agreement concerning APS001, a novel anticancer agent currently under development at Anaeropharma Science that utilizes characteristic features of Bifidobacterium longum, as well as an agreement concerning the discovery of novel anticancer agents that utilize Bifidobacterium as a drug delivery system. The two contracts...

2010-09-30 08:35:01

Tokyo, Sept 30, 2010 - (JCN Newswire) - Brain Factory Co., Ltd. and Eisai Co., Ltd. announced today that they have concluded a license agreement concerning a dihydrogen phosphonoxy methoxy derivative of ravuconazole (ravuconazole prodrug). Under the terms of the agreement, Eisai shall grant Brain Factory the exclusive rights to develop, commercialize, and sublicense ravuconazole prodrug in Japan as an ethical antimycotic for treating all types of fungal infections with the exception of Chagas...

2010-09-07 04:35:02

Tokyo, Sept 7, 2010 - (JCN Newswire) - SymBio Pharmaceuticals Limited and Eisai Co., Ltd. announced today that Eisai's Singapore subsidiary Eisai (Singapore) Pte. Ltd. launched bendamustine hydrochloride ("bendamustine") in Singapore under the brand name Symbenda(R) as a treatment for low-grade non-Hodgkin's lymphoma and chronic lymphatic leukemia.Bendamustine is the subject of a license agreement concluded between the two companies in May 2009, in which SymBio granted Eisai the exclusive...

2010-09-02 04:35:01

Tokyo, Sept 2, 2010 - (JCN Newswire) - Eisai Co., Ltd. announced today the start of the first patient enrolled clinical study with BAN2401, a novel monoclonal antibody that is being developed as a potential next-generation therapeutic treatment for Alzheimer's disease. BAN2401 is the first monoclonal antibody to selectively bind, neutralize and eliminate soluble protofibrils, the toxic amyloid-beta aggregates thought to cause Alzheimer's disease. With this new treatment approach, it is...

2010-08-26 03:13:34

Tokyo, Aug 24, 2010 - (JCN Newswire) - Eisai Co., Ltd. announced today that results of a Phase III study in epilepsy patients with refractory partial seizures demonstrate the clinical benefits of the novel investigational compound E2007 (generic name: perampanel). Discovered and developed by Eisai, perampanel is a first-in-class drug with a unique mechanism that selectively and non-competitively antagonizes AMPA-type glutamate receptors.The global study (Study 306), conducted primarily in...


Word of the Day
toccata
  • In music, a work for a keyboard-instrument, like the pianoforte or organ, originally intended to utilize and display varieties of touch: but the term has been extended so as to include many irregular works, similar to the prelude, the fantasia, and the improvisation.
This word is Italian in origin, coming from the feminine past participle of 'toccare,' to touch.
Related